Technical Analysis for AGIO - Agios Pharmaceuticals, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| B | 46.30 | -1.13% | -0.53 |
Earnings due: Oct 31
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Overbought Stochastic | Strength | 0.00% | |
| Overbought Stochastic | Strength | -1.13% | |
| Up 3 Days in a Row | Strength | -1.13% | |
| Up 4 Days in a Row | Strength | -1.13% | |
| Pocket Pivot | Bullish Swing Setup | 0.48% | |
| Stochastic Reached Overbought | Strength | 0.48% | |
| Gapped Up | Strength | 0.48% | |
| Overbought Stochastic | Strength | 0.48% | |
| Up 3 Days in a Row | Strength | 0.48% | |
| Overbought Stochastic | Strength | 2.68% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | about 13 hours ago |
| Down 1% | about 13 hours ago |
| Possible NR7 | about 14 hours ago |
| Rose Above Previous Day's High | about 17 hours ago |
| 60 Minute Opening Range Breakout | about 17 hours ago |
Get a Trading Assistant
- Earnings date: 10/31/2024
Agios Pharmaceuticals, Inc. Description
Agios Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the field of cancer metabolism and inborn errors of metabolism (IEMs) in the United States. Its products include AG-221, an oral inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein for the treatment of patients with cancers that harbor IDH2 mutations, as well as for the Type II D-2 hydroxyglutaric aciduria treatment; AG-120, an oral inhibitor of the mutated IDH1 protein for the treatment of patients with cancers that harbor IDH1 mutations; and enzyme glutaminase that converts the nutrient glutamine into the metabolite glutamate. The company's products also comprise AG-348, an oral small molecule activator of PKR enzyme for the treatment of patients with pyruvate kinase deficiency. It has a collaboration agreement with Celgene Corporation. The company was founded in 2007 and is based in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Acid Hydrogen Metabolism Organic Chemistry Glutamate Inborn Errors Of Metabolism Pyruvate Kinase Deficiency
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 53.285 |
| 52 Week Low | 20.4 |
| Average Volume | 471,219 |
| 200-Day Moving Average | 37.68 |
| 50-Day Moving Average | 44.70 |
| 20-Day Moving Average | 43.49 |
| 10-Day Moving Average | 45.44 |
| Average True Range | 1.64 |
| RSI (14) | 58.51 |
| ADX | 13.76 |
| +DI | 24.86 |
| -DI | 16.93 |
| Chandelier Exit (Long, 3 ATRs) | 42.28 |
| Chandelier Exit (Short, 3 ATRs) | 44.87 |
| Upper Bollinger Bands | 47.78 |
| Lower Bollinger Band | 39.19 |
| Percent B (%b) | 0.83 |
| BandWidth | 19.75 |
| MACD Line | 0.55 |
| MACD Signal Line | 0.12 |
| MACD Histogram | 0.4369 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 48.02 | ||||
| Resistance 3 (R3) | 48.13 | 47.67 | 47.74 | ||
| Resistance 2 (R2) | 47.67 | 47.23 | 47.62 | 47.64 | |
| Resistance 1 (R1) | 46.99 | 46.96 | 46.76 | 46.87 | 47.54 |
| Pivot Point | 46.52 | 46.52 | 46.41 | 46.47 | 46.52 |
| Support 1 (S1) | 45.84 | 46.09 | 45.61 | 45.73 | 45.06 |
| Support 2 (S2) | 45.38 | 45.81 | 45.32 | 44.96 | |
| Support 3 (S3) | 44.69 | 45.38 | 44.86 | ||
| Support 4 (S4) | 44.58 |
